Porcine reproductive and respiratory syndrome virus (PRRSV) is one of the most economically important pathogens affecting many swine-producing regions. Current vaccination strategies and antiviral drugs provide only limited protection. PRRSV infection can cleave mitochondrial antiviral signaling protein (MAVS) and inhibit the induction of type I interferon. The antiviral effector molecules that are involved in host protective responses to PRRSV infection are not fully understood.
it is the most economically significant porcine disease in China (6, 7) . At present, there are no adequate control strategies against it, due to antigenic and genomic diversity among PRRSV isolates, the persistence of the virus in infected herds, and immunological inhibition (8, 9) . PRRSV has evolved a number of mechanisms to evade the host immune response (2, 10) including inducing interleukin 10 and secretory CD83 to suppress host immune responses (11) (12) (13) and inhibiting the induction of type I interferon (IFN) (14) (15) (16) (17) . However, some host factors have been identified as having antiviral functions against PRRSV, including myxovirus resistance 2 (MX2), viperin, interferon-induced protein with tetratricopeptide repeats 3 (IFIT3), and cholesterol 25-hydroxylase (CH25H) (18) (19) (20) (21) (22) .
The innate immune response is the first line of host defense against viral infections, it is triggered by pattern recognition receptors, including Toll-like receptors, retinoic acid induced gene I (RIG-I)-like receptors and so on (23, 24) . In RIG-I-like receptor pathways, RIG-I-like RNA helicases bind to viral RNA and activate the mitochondrial antiviral-signaling protein (MAVS), which advances the signaling cascade by activating the cytosolic kinases IB kinase (IKK) and TBK1, which in turn stimulate the transcription factors NF-B and interferon regulatory factor 3 (IRF3), respectively. NF-B and IRF3 function cooperatively to induce type I IFN and other antiviral molecules (25) (26) (27) (28) . Interferon binds to their receptors, activating the JAK-STAT signaling pathway, and induces the expression of hundreds of interferon-stimulated genes (ISGs) (29) . These ISGs can target almost any step of the viral life cycle, but the complete molecular mechanisms used by these ISGs in response to different pathogens are not fully understood.
Here, in order to study the immune response of the host and enrich the data library of antiviral factors against PRRSV, we activated the immune response of Marc-145 cells by overexpressing MAVS and found that PRRSV replication was inhibited. Transcriptome analysis of the MAVS-transfected cells showed that antiviral immune responses were significantly upregulated and induced the production of type I interferon and numerous antiviral factors. Among the many other antiviral factors upregulated was a CCCH-type zinc finger antiviral protein (ZAP). We cloned the ZAP gene for further study and found that it inhibited the replication of PRRSV in Marc-145 cells, and this inhibition was quickly started during the early stage of PRRSV replication. We found that PRRSV Nsp9, an RNA-dependent RNA polymerase (RdRp), directly interacts with ZAP, and we have demonstrated that ZAP plays an important role in the antiviral response of Marc-145 cells, and when activated, can inhibit PRRSV replication. titative real-time reverse transcription-PCR (qRT-PCR). These results showed that the altered expression of these 9 genes identified by mRNA-seq was consistent with the results of qRT-PCR (Fig. 2C ). The biological processes of MAVS-upregulated genes were mainly viral defense responses, type I interferon-mediated signaling, and negative regulation of viral genome replication (Fig. 2D ). The genes associated with antiviral responses are listed in Fig. 2E . The results demonstrate that MAVS actives the host immune response, including induction of numerous antiviral factors.
Effects of the candidate novel antiviral factors on PRRSV replication. Seven MAVS-induced antiviral genes (encoding IFI6, APOBEC3H [A3H], PLSCR1, TRIM22, ZC3HAV1 [ZAP], DTX3L, and MX2) were selected for further investigation into their effects on PRRSV replication (Fig. 3A) . Western blotting results revealed that ZAP and MX2 significantly suppress PRRSV replication, whereas A3H, TRIM22, PLSCR1, and DTX3L do not (Fig. 3B) . The cell viability assay demonstrated that the growth and viability of all transfected cell populations were comparable (Fig. 3C ). The effect of ZAP-L (the long isoform of ZAP) on PRRSV replication was also examined. The results showed that the inhibitory effect of ZAP-L is similar to that of ZAP ( Fig. 3D ).
Overexpression of ZAP inhibits PRRSV replication. To further investigate the effect of ZAP on PRRSV replication, Marc-145 cells were transfected with pHA-ZAP and/or pHA-EV for 24 h and then infected with PRRSV at an MOI of 0.1. Western blotting and qRT-PCR results showed that overexpression of ZAP results in a marked decrease in N protein and PRRSV ORF7 mRNA expression in a ZAP dose-dependent manner ( Fig.  4A and B ). Progeny virus production in these supernatants was significantly decreased in a ZAP dose-dependent manner, as determined by the 50% tissue culture infective dose (TCID 50 ) ( Fig. 4C ). Indirect immunofluorescence assay (IFA) results showed that the amount of PRRSV detectable in cells, as determined by N-protein fluorescence, was reduced in a ZAP dose-dependent manner (Fig. 4D ). In addition, overexpressing ZAP significantly inhibited the replication of each of the subtype strains of PRRSV which include the classical strain S1, the highly pathogenic strain BB0907, the NADC30-like strain FJ1402, and the new subgenotype strain GD1404 (Fig. 4E ). These results show that ZAP inhibits PRRSV replication in a ZAP dose-dependent and PRRSV strainindependent manner.
Knockdown of ZAP enhances PRRSV replication. Marc-145 cells were transfected with small interfering RNA (siRNA) targeting ZAP or NC siRNA for 24 h and then challenged with PRRSV at an MOI of 0.1. At 30 h postinfection (hpi), cells were collected to determine ZAP mRNA and protein levels by qRT-PCR and Western blotting and to determine PRRSV replication. The results showed that the transcription level and protein expression of endogenous ZAP were significantly reduced by transfection of siZAP-2 and siZAP-3, while siZAP-1 had no effect on ZAP expression ( Fig. 5A and B ). Knockdown of ZAP significantly enhanced the replication of PRRSV in Marc-145 cells ( Fig. 5B and C) . Furthermore, the restriction of PRRSV replication by ZAP was restored by overexpressing ZAP in the knockdown cells ( Fig. 5D ). These results indicate that ZAP is part of the host defense mechanism against PRRSV infection.
ZAP suppresses PRRSV replication at the early stage of replication. To identify which step of the PRRSV life cycle was restricted by ZAP, viral binding and entry were explored. Two cultures each of ZAP-or empty vector (EV)-transfected Marc-145 cells were incubated with PRRSV at an MOI of 0.1 at 4°C for 1 h. One group of cells in each culture were washed with phosphate-buffered saline (PBS), and bound virus was measured by quantitating viral mRNA by qRT-PCR. The second group of cultures was shifted to 37°C for 2 h, cells were then washed to remove all unincorporated virus, and the intracellular viral RNA was quantified using qRT-PCR (Fig. 6A ). The results showed that there was no significant difference in the amount of PRRSV bound or internalized between ZAP-and EV-transfected cells (Fig. 6B ). These data demonstrate that overexpressing ZAP does not block the process of viral binding or entry.
Kinetic studies were performed to investigate the antiviral action of ZAP on PRRSV replication. The PRRSV transcriptional levels in ZAP-transfected cells were quantified by qRT-PCR at various time points postinfection, and viral N-protein expression was detected by Western blotting. The results showed there were no significant differences in transcriptional levels at 2 hpi, again demonstrating that overexpressing ZAP does not affect the entry of PRRSV into the cells. However, the amount of viral RNA was significantly reduced in ZAP-overexpressing cells from 4 hpi to the end of the assay period at 36 hpi ( Fig. 6C) . Similarly, Western blotting results showed that the expression of PRRSV N protein was significantly suppressed by ZAP ( Fig. 6D ). Taken together, these results indicate that ZAP initiates the suppression of PRRSV replication at the early stage of PRRSV replication.
Screening PRRSV proteins for interaction with ZAP. 293T cells were cotransfected with plasmids expressing hemagglutinin (HA)-tagged ZAP and Flag-tagged PRRSV proteins. Coimmunoprecipitation (co-IP) assays were performed with anti-HA polyclonal antibody (PAb) and anti-Flag monoclonal antibody (MAb) at 48 h posttransfection. The immunoprecipitation results demonstrate that HA-ZAP interacts with Flag-Nsp9 but not with the other viral proteins. (Fig. 7A ). To preclude nonspecific interaction mediated by RNA, the cell lysates were treated with RNase A prior to co-IP. The results confirmed that the interaction of ZAP and Nsp9 was RNA independent (Fig.  7B ). Furthermore, confocal microscopy illustrated the colocalization of ZAP and Nsp9 in the cytoplasm of HA-ZAP-and Flag-Nsp9-cotransfected cells (Fig. 7C ). Taken together, those data demonstrate that ZAP interacts with the Nsp9 of PRRSV.
The zinc finger domain of ZAP mediates the antiviral response and interaction with Nsp9. ZAP has a zinc finger domain at its N terminus and a WWE domain at its C terminus, whereas the ZAP long isoform (ZAP-L) also contains a poly(ADP-ribose) polymerase (PARP) domain at its C terminus (30) (Fig. 8A) . To map the functional domain of ZAP required for inhibiting PRRSV replication, we constructed several HA-tagged truncations of ZAP. Marc-145 cells were transfected with these plasmids for 24 h and then challenged with PRRSV at an MOI of 0.1. After incubation for 30 h, the cells and supernatants were harvested for Western blotting and virus titration. The results showed that ZAP-N (the zinc finger domain of ZAP) exhibited inhibition of PRRSV replication similar to that of ZAP and ZAP-L. However, the WWE domain or the PARP domain had no effect on PRRSV replication ( Fig. 8B and C), suggesting that the zinc finger domain of ZAP is necessary and sufficient for ZAP antiviral activity. Furthermore, co-IP assay results showed that Nsp9 interacts with ZAP-N as well as with ZAP and ZAP-L but not with the WWE or PARP domain ( Fig. 8D ). Collectively, these results suggested that the zinc finger domain of ZAP is crucial for its antiviral activity and its interaction with Nsp9.
The region from aa 150 to 160 of Nsp9 is required for the interaction with ZAP. To investigate the region of Nsp9 required for binding to ZAP, the spatial structures of Nsp9 of PRRSV were predicted using I-TASSER (https://zhanglab.ccmb.med.umich.edu/ I-TASSER/). The predicted structure possesses an independent domain at the N terminus (amino acids [aa] 1 to 177) and a compact structure at the C terminus (aa 449 to 643) ( Fig. 9A ). Based on these structures, five Flag-tagged truncated mutants of Nsp9-expressing plasmids were constructed, including aa 1 to 177, 178 to 449, 450 to 643, 1 to 449, and 178 to 643 ( Fig. 9B ). 293T cells were cotransfected with the Flag-tagged Nsp9 or its truncations and HA-tagged ZAP and incubated for 48 h. The co-IP results showed that the Nsp9 aa 1 to 177, Nsp9 aa 1 to 449, and the full-length Nsp9 could interact with ZAP. In contrast, ZAP had no interaction with other truncations (Fig. 9C) , indicating that the region of aa 1 to 177 of Nsp9 is responsible for the interaction with ZAP. To further narrow down the Nsp9-ZAP-interacting region of Nsp9, further truncations were made only within the region from aa 1 to 177 of Nsp9: aa 60 to 643, 119 to 643, 150 to 643, 160 to 643, and 170 to 643 (Fig. 9D) . Similarly, a co-IP assay was performed to determine the interacting region. As shown in Fig. 9E , the regions from aa 60 to 643, 119 to 643, and 150 to 643 and the full-length Nsp9 coimmunoprecipitated with ZAP, whereas the regions from aa 160 to 643 and aa 170 to 643 did not. These results suggest that the critical region of Nsp9 for interaction with ZAP is in the region of amino acids 150 to 160.
DISCUSSION
PRRSV is one of the most important economically damaging pathogens in the swine industry globally. The interaction of PRRSV and the host immune response is complicated and not fully understood. In this study, we screened several candidate antiviral factors in MAVS-mediated antiviral immune pathways by transcriptome sequencing. We found that ZAP effectively inhibits the replication of PRRSV in Marc-145 cells and that ZAP interacts with the viral RNA-dependent RNA polymerase (RdRp) Nsp9. This suggests that ZAP may play a critical role in the innate immune response to suppress PRRSV infection.
ZAP, also known as ZC3HAV1, is a CCCH-type zinc finger antiviral protein. ZAP can inhibit the replication of Moloney murine leukemia virus, Sindbis virus, Ross River virus, Ebola virus, Marburg virus, and hepatitis B virus (31) (32) (33) (34) . ZAP can directly bind viral mRNA and prevent the accumulation of viral RNA in the cytoplasm, and it can also recruit the RNA exosome to degrade target viral RNA (35) (36) (37) . In addition, ZAP inhibits human immunodeficiency virus (HIV) infection by selectively targeting multiply spliced viral RNA for degradation (38) . These findings suggest that ZAP is a trans-acting factor that modulates mRNA stability. In this study, our results showed that overexpressing ZAP does not block the process of viral binding or entry but that ZAP initiates the suppression of PRRSV replication at the early stage of PRRSV replication. At the early stage, when PRRSV replication is still in a single cycle, ZAP may interrupt viral RNA synthesis, and then ZAP may also target the viral RNA for degradation. We also note an approximately 2-fold difference in RNA replication in the presence of ZAP through about 18 hpi, which then suddenly increased to over a log by 36 hpi (Fig. 6 ). The increased difference in RNA at later times might be due to defects during the first round of replication that were independent of RNA production. ZAP preferentially targets CG dinucleotides for binding and recognition in HIV (39) . We analyzed the amount of CG dinucleotides of the PRRSV BB0907 genome in a previous study (40) . The CϩG content is 52.13%, and the relative abundance of CG dinucleotides is 1.42, which is a high relative abundance compared with a random association of mononucleotides (41) . Whether ZAP inhibits PRRSV replication by binding and degrading viral RNA requires further investigation.
PRRSV has various Nsps in replicases ORF1a and ORF1b that participate in PRRSV RNA synthesis, in particular the viral Nsp9 and RNA helicase Nsp10 (4, 36) . To investigate whether ZAP interrupts PRRSV RNA synthesis by interacting with PRRSV functional proteins, all of the viral structural and nonstructural protein genes except those for Nsp2, GP2, and GP4 were subjected to co-IP assay. The results showed that only the viral RNA polymerase Nsp9 interacts with ZAP. PRRSV Nsp9 contains a putative RNAdependent RNA polymerase (RdRp) domain at the C terminus, and the N terminus of Nsp9 has a newly identified nidovirus RdRp-associated nucleotidyltransferase (NiRAN) domain (4, 42) . PRRSV Nsp9 is considered to be a core component of the viral replication and transcription complex (RTC) (43) . PRRSV Nsp9 not only possesses RNA polymerase activity but also interacts with the N protein of PRRSV to regulate viral RNA synthesis (44) . Moreover, it has been reported that Nsp9 interacts with other cellular proteins, including annexin A2, retinoblastoma protein, and DEAD box RNA helicase 5; these interactions benefit the replication of PRRSV (45) (46) (47) . In this study, our results showed that ZAP interacts with Nsp9 and suppresses the replication of PRRSV. The regions of Nsp9 critical to the interaction with ZAP are located between amino acid residues 150 and 160, which belong to the NiRAN domain. Recent research has indicated that NiRAN is essential for replication of nidoviruses, including PRRSV. Potential functions supported by NiRAN may include nucleic acid ligation, mRNA capping, and protein-primed RNA synthesis (42) . We speculate that the interaction between ZAP and the RNA polymerase Nsp9 interferes with the functions of NiRAN and impedes the synthesis of the PRRSV genome, thereby suppressing PRRSV replication. Of course, this speculation remains to be verified in future studies.
ZAP contains four CCCH-type zinc finger motifs at its N terminus, and ZAP binds directly to specific viral RNA sequences through these zinc finger motifs (35, 37) . In this study, the zinc finger domain is also proved to be responsible for the interaction with PRRSV Nsp9. And the zinc finger domain was found to be necessary and sufficient for ZAP to restrict PRRSV replication. These results establish that the zinc finger motifs play an important role in the antiviral activity of ZAP.
In addition to acting as a cellular restriction factor against virus infection, ZAP is also a potent stimulator of signaling mediated by RIG-I during antiviral responses (48, 49) . RIG-I is an important cytosolic pattern recognition receptor (PRR) that triggers innate immune defenses against a variety of RNA viruses (25) . Here, we found that ZAP reduced the PRRSV replication at the early stage of infection. We speculate that the synthesis of the PRRSV genome was impeded by the interaction of ZAP with the viral RNA-dependent RNA polymerase (RdRp) Nsp9. Whether ZAP inhibits PRRSV replication by boosting the early antiviral response mediated by RIG-I or by interacting with other host cofactors requires further investigation.
In summary, we found that ZAP is an efficient cell-intrinsic antiviral factor against PRRSV replication due to its interaction with viral Nsp9. The critical regions of interaction between ZAP and Nsp9 were mapped to the zinc finger domain of ZAP and amino acid residues 150 to 160 of Nsp9. These findings should be helpful in understanding the host antiviral response to PRRSV infection.
MATERIALS AND METHODS

Cells and viruses.
PRRSV-permissive Marc-145 (monkey kidney) cells and human embryonic kidney (HEK293T) cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) containing 10% fetal bovine serum (Gibco) at 37°C in a humidified atmosphere containing 5% CO 2 . The highly virulent PRRSV strain BB0907 (GenBank accession no. HQ315835.1) was used for all experiments and is the strain represented by "PRRSV" in this article unless otherwise specified. The classical PRRSV strain S1, the PRRSV NADC30-like strain FJ1402 (GenBank accession no. KX169191.1), and a new subgenotype PRRSV strain, GD1404 (GenBank accession no. MF124329.1), were isolated and stored in our laboratory.
mRNA-seq. Marc-145 cells were transfected with MAVS plasmid or empty vector. After being incubated for 24, 36, and 48 h, total RNA was extracted from the transfected cells using TRIzol. An amount of 2 g of total RNA was treated twice by using a poly(A) mRNA magnetic isolation module (NEB). After selection, the mRNA was fragmented, and sequencing libraries were prepared using a Kapa Stranded RNA-Seq Library Prep kit (Illumina). Gene expression data were obtained by sequencing using an Illumina HiSeq 4000 instrument. The differentially expressed genes were considered to be significant at a Q value of Ͻ0.005 and absolute fold change of Ն2. Genes with significant similarities to the transcripts were selected for gene ontology (GO) analysis, based on the DAVID database (50) .
Construction of plasmids and transfection of cells. Seven ISGs, i.e., those for IFI6, APOBEC3H (A3H), PLSCR1, TRIM22, ZC3HAV1 (ZAP), MX2, and DTX3L, were selected from the MAVS-mediated antiviral related pathways and PCR amplified for plasmid construction. The amplicons was cloned into pCAGGS vectors (Addgene) containing a C-terminal HA tag and sequenced. Genes of PRRSV structural and nonstructural proteins were cloned into the pCI-neo vector (Promega) containing an N-terminal Flag tag. Truncations of pHA-ZAP and pFlag-Nsp9 were subcloned from the pCA-ZAP and pCI-Nsp9 plasmids, respectively. The amplification primers used are listed in Table 1 . Marc-145 and 293T cells were transfected with plasmids using Lipofectamine 3000 according to the manufacturer's instructions.
Luciferase reporter assay. Marc-145 cells cultured in 24-well plates were cotransfected with 500 ng of MAVS expressing plasmid or empty vector, 400 ng of IRF3 or NF-B luciferase reporter plasmid, and 100 ng of Renilla luciferase construct (pRL-TK), which served as an internal control. At 24 h posttransfection (hpt), the cells were harvested and the luciferase activity was measured with a dual-luciferase reporter assay system (Promega). Relative luciferase activity was normalized to that of a control. All assays were performed in triplicate.
Virus challenge and titration. To detect the effects of screened ISGs on the replication of PRRSV, Marc-145 cells were transfected with plasmids containing an HA-tagged ISG or empty vector (EV). At 24 h posttransfection, cells were challenged with PRRSV at an MOI of 0.1 (0.7 TCID 50 /cell is defined as an MOI of 1) for 30 h. To detect the effects of knockdown of ZAP on PRRSV replication, Marc-145 cells were transfected with the indicated siRNA. At 24 h posttransfection, cells were challenged with PRRSV at an MOI of 0.1 and incubated for 30 h. Virus progeny production in the supernatants was determined by TCID 50 . Briefly, Marc-145 cells were seeded into 96-well plates at 24 h before virus titration. Virus supernatants were prepared by 10-fold serial dilution, and 100-l volumes of the dilutions were added per well in replicates of eight. At 5 days postinfection, the TCID 50 was calculated using the Reed-Muench method. Cell viability assay. A cell viability assay was performed using the Cell Counting Kit-8 (CCK-8) (Beyotime) according to the manufacturer's instructions. Results were expressed relative to those for control cells, defined as 100% viability. siRNA knockdown. All siRNAs (Invitrogen) were transfected with Lipofectamine 3000 according to the manufacturer's instructions. Marc-145 cells were plated into 24-well plates, and when 60% confluent, cells were transfected with 50 pmol of siRNA. To determine the efficiency of the knockdown, total RNA was extracted from the cells at 24 h posttransfection, and endogenous ZAP mRNA was quantified by qRT-PCR. In parallel, cells were lysed, and proteins were separated by SDS-PAGE, transferred to nitrocellulose, and probed with polyclonal anti-ZAP antibodies (1:2,000) (Proteintech). The siRNA sequences are as follows: siZAP-1, 5=-CUU CUA CCA GAU CCU UAA ATT-3=; siZAP-2, 5=-GAA AUG AGU UGU GAU UUC ATT-3=; siZAP-3, 5=-GAU UCU UUA UCU GAU GUC ATT-3=. The nontargeting control siRNA (siNC) sequence is 5=-UUC UCC GAA CGU GUC ACG UTT-3=.
TABLE 1 Primers used in this study
Virus binding and entry assays. Marc-145 cells cultured in 24-well plates were transfected with either pHA-ZAP or empty vector for 24 h. For the virus binding assay, Marc-145 cells were challenged with PRRSV at an MOI of 0.1 at 4°C for 1 h to allow virions to bind to, but not enter, cells. After washing cells with cold phosphate-buffered saline (PBS), bound virions were measured by qRT-PCR. For the virus entry assay, cells were incubated with PRRSV at 4°C for 1 h, washed with cold PBS, overlaid with warmed DMEM, and incubated at 37°C for 2 h to allow virions to enter the cells (the time point at which the cells were shifted to 37°C is set as 0 h). The cells were then washed with cold alkaline high-salt solution (1 M NaCl and 50 mM sodium bicarbonate [pH 9.5]) for 3 min to remove cell-surface-associated viruses (51) . After being washed twice with cold PBS, the cells were trypsinized and collected for qRT-PCR assay. Virus entry was quantified by qRT-PCR of intracellular PRRSV RNA.
Viral replication kinetics. Marc-145 cells cultured in 12-well plates were transfected with either pHA-ZAP or empty vector for 24 h and then challenged with PRRSV at an MOI of 0.1. Cells were collected at various time points over 36 h after infection and divided for RNA and protein extraction. PRRSV replication kinetics were analyzed at the viral transcription level by qRT-PCR, and the viral protein level was measured by Western blotting.
IFA. For indirect immunofluorescence assay (IFA), Marc-145 cells (transfected or infected) plated in 24-well plates were washed three times with PBS, fixed for 20 min with 4% paraformaldehyde, and then permeabilized for 30 min with 0.1% Triton X-100. The fixed cells were incubated with a monoclonal antibody to PRRSV N protein (2H7, made in our laboratory) (1:100) for 2 h at 37°C. Following three washes with PBS, the cells were incubated with Alexa Fluor 488-conjugated goat anti-mouse IgG (1:100) (Beyotime) for 1 h at 37°C. After washing again with PBS, fluorescence images were observed using fluorescence microscopy (Nikon).
qRT-PCR. For quantitative real-time RT-PCR (qRT-PCR), total RNAs were isolated from PRRSVinfected cells using the Total RNA kit (Omega) and reverse transcribed into cDNA with HiScript QRT SuperMix for qPCR (Vazyme) according to the manufacturer's instructions. qRT-PCR primers are listed in Table 1 .
Co-IP and Western blotting. For the coimmunoprecipitation assay, 293T cells were cotransfected with HA-tagged ZAP and Flag-tagged PRRSV genes or plasmids expressing Nsp9 truncations. At 48 h posttransfection, cells were washed with cold PBS and lysed with cell lysis buffer for Western blotting and IP (Beyotime). Cell lysates were centrifuged at 12,000 ϫ g for 10 min, supernatants were incubated with mouse anti-Flag monoclonal antibody (1 g) (Abmart) or rabbit anti-HA polyclonal antibody (1 g) (Proteintech) at 4°C for 8 h, and then 30 l of protein A/G-agarose (Beyotime) was added to each lysate and incubation continued for 3 h at 4°C. The beads were collected by centrifugation at 2,500 ϫ g for 5 min and washed five times with cold PBS. The bound proteins were subjected to SDS-PAGE, transferred to nitrocellulose, and probed with rabbit anti-FLAG PAb (1:5,000) or mouse anti-HA MAb (1:5,000) (Proteintech).
For Western blotting, equal amounts of protein were subjected to SDS-PAGE and electrotransferred to nitrocellulose membranes (Pall). Membranes were blocked in 5% nonfat milk for 2 h at room temperature and then incubated with the indicated antibodies. Following three washes in PBS-Tween, membranes were incubated with either horseradish peroxidase (HRP)-conjugated goat anti-rabbit or goat anti-mouse antibody (1:1000) (Beyotime) for 1 h at room temperature. After washing, proteins were detected using an ECL kit (Tanon).
Confocal microscopy. 293T cells were cotransfected with pHA-ZAP and pFlag-Nsp9 for 48 h. Transfected cells were then fixed and permeabilized with precooled isometric methyl alcohol and acetone (1:1) for 10 min, blocked in 1% bovine serum albumin for 30 min, and then incubated with mouse anti-Flag (1:1,000) or rabbit anti-HA (1:100) for 2 h at 37°C. After washing with PBS, the cells were incubated with Alexa Fluor 488-conjugated goat anti-mouse IgG(HϩL) and Alexa Fluor 647-conjugated goat anti-rabbit IgG(HϩL) (1:200) (Beyotime) for 1 h at 37°C. Cells were washed again with PBS and then stained with 4',6-diamidino-2-phenylindole (DAPI) for 10 min at room temperature. Cells were examined using confocal microscopy (Nikon A1).
Statistical analysis. Statistical analysis was performed using GraphPad Prism5 software. Results were expressed as the mean Ϯ standard deviation (SD). Differences between groups were examined for statistical significance using one-way or two-way analysis of variance (ANOVA). The asterisks in the figures indicate significant differences (*, P Ͻ 0.05; **, P Ͻ 0.01; ns, not significant).
Data availability. All sequencing data files are available through the NCBI GEO repository as record GSE111530.
